Binding of losartan to angiotensin AT1 receptors increases dopamine D1 receptor activation

Journal of the American Society of Nephrology

Volumn 23, Issue 3, 2012, Pages 421-428

  Li, Dong ^a,c   Scott, Lena ^a   Crambert, Susanne ^a   Zelenin, Sergey ^a   Eklöf, Ann Christine ^a   Di Ciano, Luis ^b   Ibarra, Fernando ^b   Aperia, Anita ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INSTITUTO DE INVESTIGACIONES MÉDICAS ALFREDO LANARI   (Argentina)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANGIOTENSIN 1 RECEPTOR; CYCLIC AMP; DOPAMINE 1 RECEPTOR; LOSARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; KIDNEY PROXIMAL TUBULE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RENOVASCULAR HYPERTENSION;

EID: 84863251389     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011040344     Document Type: Article

References (31)

1. Aperia A, Bertorello A, Seri I: Dopamine causes inhibition of Na+-K+-ATPase activity in rat proximal convoluted tubule segments. Am J Physiol 252: F39-F45, 1987
2. Zeng C, Jose PA: Dopamine receptors: Important antihypertensive counterbalance against hypertensive factors. Hypertension 57: 11-17, 2011
3. Aperia A, Holtbäck U, Syrén ML, Svensson LB, Fryckstedt J, Greengard P: Activation/deactivation of renal Na+,K(+)-ATPase: A final common pathway for regulation of natriuresis. FASEB J 8: 436-439, 1994 (Pubitemid 24155957)
4. Zeng C, Wang Z, Hopfer U, Asico LD, Eisner GM, Felder RA, Jose PA: Rat strain effects of AT1 receptor activation on D1 dopamine receptors in immortalized renal proximal tubule cells. Hypertension 46: 799-805, 2005 (Pubitemid 43186755)
5. Gildea JJ: Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance. Curr Opin Nephrol Hypertens 18: 28-32, 2009
6. Khan F, Spicarová Z, Zelenin S, Holtbäck U, Scott L, Aperia A: Negative reciprocity between angiotensin II type 1 and dopamine D1 receptors in rat renal proximal tubule cells. Am J Physiol Renal Physiol 295: F1110-F1116, 2008
7. Wang L, Martin B, Brenneman R, Luttrell LM, Maudsley S: Allosteric modulators of G protein-coupled receptors: Future therapeutics for complex physiological disorders. J Pharmacol Exp Ther 331: 340-348, 2009
8. Jordan BA, Devi LA: G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399: 697-700, 1999 (Pubitemid 29289066)
9. Smith NJ, Milligan G: Allostery at G protein-coupled receptor homoand heteromers: Uncharted pharmacological landscapes. Pharmacol Rev 62: 701-725, 2010
10. Ferré S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, Fuxe K, George SR, Javitch JA, Lohse MJ, Mackie K, Milligan G, Pfleger KD, Pin JP, Volkow ND, Waldhoer M, Woods AS, Franco R: Building a new conceptual framework for receptor heteromers. Nat ChemBiol 5: 131-134, 2009
11. Xu F, Mao C, Liu Y, Wu L, Xu Z, Zhang L: Losartan chemistry and its effects via AT1 mechanisms in the kidney. Curr Med Chem 16: 3701-3715, 2009
12. Ruilope LM: Angiotensin receptor blockers: RAAS blockade and renoprotection. Curr Med Res Opin 24: 1285-1293, 2008
13. Smith DH: Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 68: 1207-1225, 2008
14. Aulakh GK, Sodhi RK, Singh M: An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. Life Sci 81: 615-639, 2007 (Pubitemid 47271905)
15. Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK: Losartan versus valsartan in thetreatment ofpatients with mildtomoderate essential hypertension: Data from a multicenter, randomized, doubleblind, 12-week trial. Clin Ther 23: 1166-1179, 2001 (Pubitemid 32804112)
16. Bhuiyan MA, Ishiguro M, Hossain M, Nakamura T, Ozaki M, Miura S, Nagatomo T: Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling. Life Sci 85:136-140, 2009
17. Oliveira L, Costa-Neto CM, Nakaie CR, Schreier S, Shimuta SI, Paiva AC: The angiotensin II AT1 receptor structure-activity correlations in the light of rhodopsin structure. Physiol Rev 87: 565-592, 2007 (Pubitemid 47086283)
18. Harrison-Bernard LM, Navar LG, Ho MM, Vinson GP, el-Dahr SS: Immunohistochemical localization of ANGII AT1 receptor in adult rat kidney using a monoclonal antibody. Am J Physiol 273: F170-F177, 1997
19. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG: Dopamine receptors: From structure to function. Physiol Rev 78: 189-225, 1998 (Pubitemid 28070979)
20. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T: International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52: 415-472, 2000
21. Eklöf AC, Aperia A: Renal hypertension following aortic constriction is abolished by angiotensin II converting enzyme inhibitor, but not by low-salt diet. Acta Physiol Scand 139: 435-440, 1990
22. Eklöf AC, Holtbäck U, Sundelöf M, Chen S, Aperia A: Inhibition of COMT induces dopamine-dependent natriuresis and inhibition of proximal tubular Na+,K+-ATPase. Kidney Int 52: 742-747, 1997 (Pubitemid 27402374)
23. Buckley JP, Bickerton RK, Halliday RP, Kato H: Central effects of peptides on the cardiovascular system. Ann N Y Acad Sci 104: 299-311, 1963
24. Rettig R, Ganten D, Lang RE, Unger T: The renin-angiotensin system in the central control of blood pressure. Eur Heart J 8[Suppl B]: 129-132, 1987 (Pubitemid 17091722)
25. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG: Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606-612, 1996 (Pubitemid 26052818)
26. Peciña S, Cagniard B, Berridge KC, Aldridge JW, Zhuang X: Hyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet rewards. J Neurosci 23: 9395-9402, 2003 (Pubitemid 37323039)
27. Neuvonen PJ, Westermann E: On the cardiovascular action of dopamine in rats. Naunyn Schmiedebergs Arch Pharmacol 280: 363-371, 1973
28. Carey RM: Angiotensin type-1 receptor blockade increases ACE 2 expression in the heart. Hypertension 43: 943-944, 2004
29. Ozono R, O'Connell DP, Vaughan C, Botkin SJ, Walk SF, Felder RA, Carey RM: Expression of the subtype 1A dopamine receptor in the rat heart. Hypertension 27: 693-703, 1996 (Pubitemid 26084637)
30. Li J, Zelenin S, Aperia A, Aizman O: Low doses of ouabain protect from serum deprivation-triggered apoptosis and stimulate kidney cell proliferation via activation of NF-kappaB. J Am Soc Nephrol 17: 1848-1857, 2006 (Pubitemid 44036169)
31. Scott L, Zelenin S, Malmersjö S, Kowalewski JM, Markus EZ, Nairn AC, Greengard P, Brismar H, Aperia A: Allosteric changes of the NMDA receptor trap diffusible dopamine 1 receptors in spines. Proc Natl Acad Sci USA 103: 762-767, 2006 (Pubitemid 43153099)